BofA maintains Buy rating and $804 price target on Argenx due to strong growth prospects

From Yahoo Finance: 2025-06-30 11:31:00

Argenx SE (NASDAQ:ARGX) is one of the 11 Best Strong Buy Stocks to Invest in Now. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating with an $804 price target, citing growth prospects of Vyvgart in treating CIDP and gMG. Vyvgart has shown efficacy comparable to IVIg, leading to a positive market outlook for Argenx SE (NASDAQ:ARGX).

Vyvgart’s promising efficacy and safety profile make it a leading choice in treating gMG. The expected approval of the pre-filled syringe (PFS) may further boost Vyvgart’s adoption in large hospitals and rural areas. Argenx SE (NASDAQ:ARGX) is a global immunology company developing treatments for severe autoimmune diseases, operating in the US, Japan, EMEA, and China.

While ARGX shows investment potential, certain AI stocks offer greater upside with lower risk. For an undervalued AI stock poised to benefit from Trump-era tariffs and onshoring trends, check out the best short-term AI stock. For more insights on stock trends, read about The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.



Read more at Yahoo Finance: BofA Remains Bullish on Argenx (ARGX) With a Buy Rating and $804 PT